Aralez Pharmaceuticals Inc (TSE:ARZ) Director Seth Rudnick bought 5,000 shares of Aralez Pharmaceuticals stock in a transaction dated Wednesday, March 15th. The shares were acquired at an average cost of C$2.37 per share, for a total transaction of C$11,850.00.
Aralez Pharmaceuticals Inc (TSE:ARZ) traded up 4.30% during trading on Monday, hitting $3.15. The stock had a trading volume of 105,829 shares. Aralez Pharmaceuticals Inc has a 12 month low of $2.77 and a 12 month high of $8.75. The stock has a 50 day moving average price of $5.11 and a 200-day moving average price of $6.06. The stock’s market cap is $206.33 million.
Your IP Address:
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.